DURECT (NASDAQ:DRRX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of DURECT (NASDAQ:DRRX – Free Report) in a research note published on Sunday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock. Separately, HC Wainwright restated a “neutral” rating on shares of DURECT in a report on Thursday, November 14th. View Our Latest Report on DRRX […]

Leave a Reply

Your email address will not be published.

Previous post **Scilex Holding Co Changes Record Date for Dividend Payment****
Next post Pason Systems Inc. (OTCMKTS:PSYTF) Short Interest Update